Navigation Links
French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec
Date:9/1/2010

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec -- CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, Acquisitions, Mergers and Takeovers, New Products & Services Click to view news release full screen  

French Laboratoires Thea Acquires the Mydriasert(R) ophthalmic Insert From Carl Zeiss Meditec

 

CLERMONT-FERRAND, France, September 1, 2010 /PRNewswire/ -- Laboratoires Thea, the leading independent ophthalmic group in Europe, completes its innovative product range with the announcement of the final acquisition of Mydriasert(R). Mydriasert(R), the 1st mydriatic ophthalmic insert, is indicated for dilated fundus examination (DFE) or cataract surgery, the most widely implemented surgical procedure. Regarding cataract surgery, the market represents close to 300 000 procedures in the UK and Ireland and 3 million in Europe each year.

"This acquisition represents a significant addition to our product range and is completely in line with our strategy to become a leading provider of ophthalmic products. Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery," according to Laboratoires Thea COO Jean-Frederic Chibret. The agreement with Carl Zeiss Meditec includes the acquisition of the production site of Mydriasert(R) located in La Rochelle, France along with relevant staff. Mydriasert(R) is already commercialized in five European countries. Thanks to this agreement, Carl Zeiss Meditec will continue to concentrate on its core activities. Laboratoires Thea will develop sales through their subsidiaries and distributors.

Mydriasert(R) provides a genuine alternative to the mydriatic eye drops that are commonly used for mydriasis.

Mydriasert(R) allows one to obtain an effective and stable mydriasis with just one simple medical act which helps to avoid repeat installations of different mydriatic eye drops either for surgical procedures or diagnostic purposes.

In comparison to traditional mydriatic eye drops, Mydriasert(R) allows for fewer nursing procedures, this in turn helps to free up nursing time, reduce the risk of human errors and allows healthcare staff to spend more time with their patients[1]. The insert contains neither preservatives nor solvents.

This device, shaped like an oblong tablet, is applied beneath the eyelid and disperses both phenylephrin hydrochlorid and tropicamide, whose mechanisms of action are synergistic. Indeed, the alpha-sympathomimetic activity of phenylephrin induces an increase in pupil diameter, while the anti-cholinergic activity of tropicamide prevents the iris from contracting.

Heading towards new technologies

The acquisition of this French technology offers Thea new research and development opportunities. The system is comprised of a sterile, bio-compatible and porous matrix containing the ingredients which are gradually released into the lower conjunctival sac of the eye. The clinical situations in which it may be interesting to control the quantities of active ingredients administered onto the ocular surface are indeed quite numerous.

About Laboratoires Thea

Laboratoires Thea is the leading independent ophthalmic group in Europe. Founded in 1994, the company is a family business built on the heritage of over 150 years experience of the Chibret Family in Ophthalmology.

Today, Laboratoires Thea is ranked 3rd in France, 6th in Europe and 7th worldwide in the field of Ophthalmology. The company is present in 65 countries, owns 11 subsidiaries in Europe and had a turnover of EUR 171 million in 2009.[2]

References

---------------------------------

[1] Korobelnik JF, Tavera C, Renaud-Rougier MB, El Meski S, Colin J.; The Mydriasert insert: an alternative to eye drops for preangiographic mydriasis; Le Journal Francais d'Ophtalmologie 2004 Oct;27(8):897-902

[2] http://www.laboratoires-thea.com/ Media contact: Burson-Marsteller France Linda.pavy@bm.com Tel. +33-1-41-86-76-26 - Cell: +33-6-07-59-43-95
'/>"/>

SOURCE Laboratoires Thea
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
4. ResMed Acquires Laboratoires Narval
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
7. U.S. Preventive Medicine Acquires Specialty Disease Management
8. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
9. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
10. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced ... presenting at Source Capital Group,s 2016 Disruptive Growth & Healthcare ... 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. Joyce ... at 3:15 p.m. ET. http://www.aethlonmedical.com .  The webcast ... conclusion of the live event. The panel discussion will not ...
(Date:2/5/2016)... , Feb. 5, 2016 Dehaier ... Medical" or the "Company"), which develops, markets and ... in China and international ... plan which aims to concentrate the Company,s resources ... sleep respiratory business and to focus more on ...
(Date:2/5/2016)... 2016  Henry Schein, Inc. (NASDAQ: HSIC ), the ... to office-based dental, animal health and medical practitioners, announced ... acquire a majority ownership interest in Dental Cremer S.A., ... Brazil . --> ... is the dental distribution business of Cremer S.A. With ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... ... the addition of micro-needling services in their Napa Valley office. The technique utilizes ... Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter of ... at the La Valencia Hotel in San Diego, California to discuss changes in ... year’s most outstanding franchise, walking away with the coveted David Wright Award of ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Give To ... users to search for and donate to Give To Cure’s campaign that is crowdfunding ... that lets users make and share payments through a smart device. In 2015 alone, ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... At its ... of Patrick McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds ... of the Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat ...
Breaking Medicine News(10 mins):